Key stats
About iShares Neuroscience and Healthcare ETF
Home page
Inception date
Aug 24, 2022
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
BlackRock Fund Advisors
Distributor
BlackRock Investments LLC
ISIN
US46436E3532
IBRN is the first ETF to have a global pure-play bet on neurosciences that specifically focuses on research, development, or manufacturing of neurology biopharmaceuticals or neurological devices. These are typically associated with the treatment of neurological disorders. The index includes companies in the sub-industries classified as either/or Neurology Biopharmaceuticals and Neurology Devices by the FactSet RBICS. Eligible companies must have 50% of their annual revenues or, for pre-revenue companies, their primary business must be under listed sub-industries. Companies whose business description, trade names, or supply chain relationships indicate involvement with psychedelics or cannabis, based on an analysis using FactSet keyword data, are explicitly excluded. Eligible equities include large- to small-cap companies that meet liquidity and tradability criteria. The market cap-weighted index is reviewed and reconstituted semi-annually starting March and rebalanced quarterly.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.51%
Health Technology96.99%
Technology Services2.52%
Bonds, Cash & Other0.49%
Miscellaneous0.27%
Cash0.22%
Stock breakdown by region
North America67.45%
Europe22.77%
Asia6.91%
Oceania2.87%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
IBRN invests in stocks. The fund's major sectors are Health Technology, with 96.99% stocks, and Technology Services, with 2.52% of the basket. The assets are mostly located in the North America region.
IBRN top holdings are Supernus Pharmaceuticals, Inc. and argenx SE Sponsored ADR, occupying 5.01% and 4.63% of the portfolio correspondingly.
IBRN last dividends amounted to 0.10 USD. The year before, the issuer paid 0.01 USD in dividends, which shows a 93.77% increase.
IBRN assets under management is 3.82 M USD. It's risen 6.91% over the last month.
IBRN fund flows account for 0.00 USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, IBRN pays dividends to its holders with the dividend yield of 0.40%. The last dividend (Dec 20, 2024) amounted to 0.10 USD. The dividends are paid annually.
IBRN shares are issued by BlackRock, Inc. under the brand iShares. The ETF was launched on Aug 24, 2022, and its management style is Passive.
IBRN expense ratio is 0.47% meaning you'd have to pay 0.47% of your investment to help manage the fund.
IBRN follows the NYSE FactSet Global Neuro Biopharma and MedTech Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
IBRN invests in stocks.
IBRN price has risen by 7.02% over the last month, and its yearly performance shows a 5.53% increase. See more dynamics on IBRN price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 9.86% over the last month, showed a 10.66% increase in three-month performance and has decreased by −1.41% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 9.86% over the last month, showed a 10.66% increase in three-month performance and has decreased by −1.41% in a year.
IBRN trades at a premium (0.12%) meaning the ETF is trading at a higher price than the calculated NAV.